Literature DB >> 16970841

Tuberculosis and HIV: Implications in the developing world.

Macarthur Charles1, Jean William Pape.   

Abstract

Developing countries bear the brunt of the epidemics of AIDS and tuberculosis (TB), and the management of patients with both diseases poses a particular challenge in these settings. In this article, we review implications for the twin epidemics of HIV and TB for the developing world with respect to diagnosis, prevention, treatment and integration of national TB and HIV programs.

Entities:  

Mesh：

Year:  2006        PMID： 16970841     DOI： 10.1007/BF02696658

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN： 1548-3568            Impact factor:   5.495


  31 in total

1.  HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers.

Authors:  P Sonnenberg; J Murray; J R Glynn; S Shearer; B Kambashi; P Godfrey-Faussett
Journal:  Lancet       Date:  2001-11-17       Impact factor: 79.321

2.  Risk factors for active tuberculosis after antiretroviral treatment initiation in Abidjan.

Authors:  Catherine Seyler; Siaka Toure; Eugène Messou; Dominique Bonard; Delphine Gabillard; Xavier Anglaret
Journal:  Am J Respir Crit Care Med       Date:  2005-04-01       Impact factor: 21.405

3.  Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.

Authors:  Marc Weiner; Debra Benator; William Burman; Charles A Peloquin; Awal Khan; Andrew Vernon; Brenda Jones; Claudia Silva-Trigo; Zhen Zhao; Thomas Hodge
Journal:  Clin Infect Dis       Date:  2005-04-14       Impact factor: 9.079

4.  Risk factors and outcome of human immunodeficiency virus-infected patients with sporadic multidrug-resistant tuberculosis in New York City.

Authors:  S B Mannheimer; K A Sepkowitz; M Stoeckle; C R Friedman; A Hafner; L W Riley
Journal:  Int J Tuberc Lung Dis       Date:  1997-08       Impact factor: 2.373

5.  Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2002-03-15       Impact factor: 17.586

6.  Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial.

Authors:  D W Fitzgerald; M Desvarieux; P Severe; P Joseph; W D Johnson; J W Pape
Journal:  Lancet       Date:  2000-10-28       Impact factor: 79.321

7.  Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis.

Authors:  William Burman; Debra Benator; Andrew Vernon; Awal Khan; Brenda Jones; Claudia Silva; Chris Lahart; Stephen Weis; Barbara King; Bonita Mangura; Marc Weiner; Wafaa El-Sadr
Journal:  Am J Respir Crit Care Med       Date:  2005-08-18       Impact factor: 21.405

8.  DNA fingerprint changes in tuberculosis: reinfection, evolution, or laboratory error?

Authors:  Judith R Glynn; Malcolm D Yates; Amelia C Crampin; Bagrey M Ngwira; Frank D Mwaungulu; Gillian F Black; Steven D Chaguluka; Donex T Mwafulirwa; Sian Floyd; Caroline Murphy; Francis A Drobniewski; Paul E M Fine
Journal:  J Infect Dis       Date:  2004-08-03       Impact factor: 5.226

9.  Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study.

Authors:  Motasim Badri; Douglas Wilson; Robin Wood
Journal:  Lancet       Date:  2002-06-15       Impact factor: 79.321

10.  Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use.

Authors:  Richard E Nettles; Dana Mazo; Karla Alwood; Regina Gachuhi; Gina Maltas; Karen Wendel; Wendy Cronin; Nancy Hooper; William Bishai; Timothy R Sterling
Journal:  Clin Infect Dis       Date:  2004-02-17       Impact factor: 9.079
View more
  5 in total

1.  CD46 engagement on human CD4+ T cells produces T regulatory type 1-like regulation of antimycobacterial T cell responses.

Authors:  Steven M Truscott; Getahun Abate; Jeffrey D Price; Claudia Kemper; John P Atkinson; Daniel F Hoft
Journal:  Infect Immun       Date:  2010-10-04       Impact factor: 3.441

2.  6-Oxo and 6-thio purine analogs as antimycobacterial agents.

Authors:  Ashish K Pathak; Vibha Pathak; Lainne E Seitz; William J Suling; Robert C Reynolds
Journal:  Bioorg Med Chem       Date:  2013-02-04       Impact factor: 3.641

3.  Application of genotype MTBDRplus in rapid detection of the Mycobacterium tuberculosis complex as well as its resistance to isoniazid and rifampin in a high volume laboratory in Southern China.

Authors:  Lei Zhang; Yuanxing Ye; Lina Duo; Tingting Wang; Xingbo Song; Xiaojun Lu; Binwu Ying; Lanlan Wang
Journal:  Mol Biol Rep       Date:  2010-09-18       Impact factor: 2.316

4.  Refining dataset curation methods for deep learning-based automated tuberculosis screening.

Authors:  Tae Kyung Kim; Paul H Yi; Gregory D Hager; Cheng Ting Lin
Journal:  J Thorac Dis       Date:  2020-09       Impact factor: 2.895

5.  Synthesis of deoxygenated alpha(1-->5)-linked arabinofuranose disaccharides as substrates and inhibitors of arabinosyltransferases of Mycobacterium tuberculosis.

Authors:  Ashish K Pathak; Vibha Pathak; William J Suling; James R Riordan; Sudagar S Gurcha; Gurdyal S Besra; Robert C Reynolds
Journal:  Bioorg Med Chem       Date:  2008-11-18       Impact factor: 3.641
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.